All data are based on the daily closing price as of September 28, 2026
l
Lunit
328130.KQ
8.58 USD
0.43
+5.28%
Overview
Last close
8.58 usd
Market cap
638.54M usd
52 week high
42.56 usd
52 week low
5.98 usd
Target price
6.61 usd
Valuation
P/E
N/A
Forward P/E
N/A
Price/Sales
7.9552
Price/Book Value
2.2025
Enterprise Value
482.99M usd
EV/Revenue
6.5668
EV/EBITDA
-45.3273
Key financials
Revenue TTM
67.47M usd
Gross Profit TTM
67.47M usd
EBITDA TTM
-43.69M usd
Earnings per Share
N/A usd
Dividend
N/A usd
Total assets
352.35M usd
Net debt
N/A usd
About
Lunit Inc. provides AI-powered software and solutions for cancer diagnostics and therapeutics in South Korea. It offers AI solution for chest X-ray and mammography, as well as AI solution for digital breast tomosynthesis, and AI-powered biomarker for immune phenotyping and PD-L1 biomarker analyzer. The company has a strategic collaboration with AstraZeneca for the development of Lunit SCOPE Genotype Predictor, an AI-powered tool capable of analyzing H&E slide images to predict the likelihood of the tumor harboring NSCLC driver mutations, such as Epidermal Growth Factor Receptor mutations; with Agilent Technologies Inc. to create advanced solutions that meet the demand of novel and complex biomarker assays in drug development; and with Daiichi Sankyo Company, Limited to accelerate biomarker discovery and translational research. Lunit Inc. was founded in 2013 and is based in Seoul, South Korea.